Day 2 Program

Translational Controversies: ADCs, Targeted Therapy, or Chemo?

Day 2: December 10, 2025

1:00 PM–2:15 PM CST

Stars at Night 3-4

Session Details

This session examines the evolving role of antibody-drug conjugates (ADCs) in breast cancer, debating whether they function primarily as targeted therapies or as chemotherapy, with insights from pathology and clinical evidence.

Moderator

David Rimm, Yale School of Medicine, New Haven, CT

CT1-01

HER2 low/ultralow: what the pathologist sees

Dennis Sgroi, Massachusetts General Hospital, Boston, MA

CT1-02

Evidence that ADCs are targeted therapy

Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center, New York, NY

CT1-03

Evidence that ADCs are chemotherapy

Sara A Hurvitz, Fred Hutchinson Cancer Center, Bellevue, WA